6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 17-20, 2011, Rome

Conference Reports for NATAP


6th IAS Conference on HIV Pathogenesis Treatment and Prevention July 17-20, 2011, Rome

	Safety and efficacy of etravirine in HIV-1-infected, treatment-experienced children and adolescents (6 to <18 years): Week 24 primary analysis of the Phase II PIANO study - (08/04/11) The MONET trial: Week 144 analysis of efficacy of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs, for patients with HIV RNA <50 copies/mL at baseline - (08/04/11) The SENSE trial: Final 48-week analysis of etravirine (ETR) versus efavirenz (EFV) in treatment-naïve patients - (08/04/11) Long-term safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in ARTEMIS - (08/04/11) STEAL Study 2 Yrs Followup: Tenofovir Speeds BMD Loss vs Abacavir, But Does Not Raise Fracture Risk Over 2 Years Followup; Lower Fat Mass Also Predicts Bone Loss - written by Mark Mascolini - (08/01/11) HIV Complications & It's Treatment, Opportunistic Infections, New ART Drugs, Preventing HIV Transmission: IAS. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome 17-20 July, 2011 Written by Pablo Tebas, MD University of Pennsylvania. - (08/01/11) Women With HIV Have Lower Mortality Than Men in Europe, But Not in North America - written by Mark Mascolini - (08/01/11) Bone Loss Boosts Cardiovascular Risk 77% in French Aquitaine Cohort - written by Mark Mascolini - (08/01/11) Kidney Risk & ARTs in Aquitaine Cohort - written by Mark Mascolini - (08/01/11) HIV Prevention Report at IAS 2011 by Jared Baeten, MD & Connie Cellum, MD - (08/01/11) High Rates of Airflow Obstruction, Emphysema in Heavy-Smoking Spanish Group: average age 45...37% emphysema...marijuana doubled risk - (07/29/11) Microbial Translocation and Hepatitis C Disease Progression among HIV-infected Women - (07/27/11) Efficacy of maraviroc administered once-daily or twice-daily with boosted protease inhibitors to treatment-experienced patients - (07/27/11) 48 Week Results of Once-Daily Maraviroc (MVC) 150 mg in Combination with Ritonavir-Boosted Atazanavir (ATV/r) Compared to Emtricitabine/Tenofovir (FTC/TDF) + ATV/r in Treatment-Naïve Patients Infected with R5 HIV-1 (Study A4001078) - (07/27/11) Biomarkers Predict Hepatic Flares and Death in Hepatitis-Coinfected People Starting ART - written by Mark Mascolini - (07/26/11) Age, Race, Gender--But Not HIV--Tied to Hearing Loss in HIV+ People - written by Mark Mascolini - (07/26/11) Short-Term ART After Early Infection Does Not Delay AIDS or Death - written by Mark Mascolini - (07/26/11) Virologic Failure Rate Plummets From 31% to 5% in France From 1997 Through 2009 - written by Mark Mascolini - (07/26/11) Progressive Histological Liver Improvement After SVR in HCV/HIV Coinfected Patients Using Transient Elastography (Fibroscan) - (07/25/11) Temporal Trends in Liver-Related Mortality in a Prospective Cohort of HIV-Infected Patients in Spain 1997-2008: HCV/HIV Coinfected Death Rates Increase While Rates Decline Among HCV-/HIV+ - (07/25/11) Sustained Efficacy and Tolerability of Raltegravir after 240 Weeks of Combination ART in Treatment-Naive HIV-1 Infected Patients: Final Analysis of Protocol 004 - (07/25/11) DIONE - 24 week efficacy, safety, tolerability and pharmacokinetics of DRV/r QD in treatment-naïve adolescents, 12 to <18 years - (07/25/11) Cognitive Impairment Persists: Prevalence and risk factors for HIV associated neurococognitive disorders (HAND), 1996 to 2010: results from an observational cohort - (07/25/11) Prevalence and risk factors for HIV associated neurococognitive disorders (HAND), 1996 to 2010: results from an observational cohort - (07/25/11) Doubled Rate of Nonmelanoma Skin Cancer With HIV in California Comparison - written by Mark Mascolini - (07/24/11) Minority species resistance (Ultra-Deep Sequencing) present at screening does not affect outcomes at Week 48 in lersivirine (UK-453,061) Phase 2b study A5271015 in treatment-naïve patients - (07/24/11) Efficacy and safety of lersivirine vs efavirenz in antiretroviral treatment-naïve HIV-1-infected patients: Week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, Phase 2b trial (Study A5271015) - (07/23/11) More Than 25% in HIV-Positive SUN Study Cohort Have Insulin Resistance - written by Mark Mascolini - (07/22/11) CD4 Gains on cART Lower AIDS/Death Risk Even With High Starting CD4 Count - written by Mark Mascolini - (07/22/11) TDF/FTC PrEP Durable in MSM, But MSM and Transgender Responses Differ - written by Mark Mascolini - (07/22/11) Antiretroviral drugs and incidence of chronic kidney disease, ANRS CO3 Aquitaine Cohort, France, 2004-2008 - (07/23/11) Safety Profile of Dolutegravir (DTG, S/GSK1349572), a Next Generation Integrase Inhibitor (INI) in Combination Therapy in Antiretroviral (ART)-naïve and ART-experienced Adults from Phase 2b Studies - (07/23/11) Switching from ABC/3TC to TDF/FTC Trims Risk of Virologic Failure - written by Mark Mascolini - (07/22/11) SWIFT Study: Switching From Lamivudine/Abacavir (3TC/ABC) to Emtricitabine/Tenofovir DF (FTC/TDF) - (07/22/11) The Rome Statement for an HIV Cure: Major HIV/AIDS Stakeholders Call for HIV Cure Research to be Accelerated: sign onto this letter - (07/20/11) ViiV 'Next Generation' Integrase Dolutegravir, 48 Weeks SPRING-1 Study Naives - (07/21/11) The Rome Statement for an HIV Cure: Major HIV/AIDS Stakeholders Call for HIV Cure Research to be Accelerated: sign onto this letter - (07/20/11) First-Line Once-Daily Maraviroc Plus ATV/r Versus Triple Therapy - written by Mark Mascolini - (07/20/11) A Look Back at Once-Daily 150-mg Maraviroc for Experienced in MOTIVATE Trials - written by Mark Mascolini - (07/20/11) Frailty Rate in HIV+ mid-50 Women Matches Rate in 70-Year-Olds Without HIV - written by Mark Mascolini - (07/20/11) Heart Disease Signal and Low Femoral Density Linked in People With HIV - written by Mark Mascolini - (07/20/11) Elvitegravir Not Inferior to Raltegravir in Treatment-Experienced: Phase 3 - written by Mark Mascolini - (07/20/11) Tobira Therapeutics Presents Pharmacokinetics and Safety Data that Support Coadministration of Cenicriviroc with Tenofovir DF in Healthy Adults - (07/20/11) IAS: PrEP Results Surprised Researchers - (07/20/11) Elvitegravir Once Daily is Non-Inferior to Raltegravir Twice Daily in Treatment-Experienced Patients: 48 Week Results From a Phase 3 Multicenter, Randomized Double-Blind Study - (07/20/11) Natural controllers of HIV infection are susceptible to immune perturbations similar to those associated with normal aging - implications for women aging with HIV infection - (07/20/11) Pooled Week 96 efficacy, resistance and safety results from the double-blind, randomised, Phase III trials comparing rilpivirine (RPV, TMC278) versus efavirenz (EFV) in treatment-naïve, HIV-1-infected adults - (07/20/11) Interaction of Vascular and Bone Disease in HIV Infected Patients: Coronary Artery Calcification is associated with femoral but not lumbar spine mineral density - (07/19/11) Atazanavir Without Ritonavir as Simpler Maintenance: 144-Week ARIES Results - written by Mark Mascolini - (07/19/11) Late HIV Diagnosis Raises ICU Admission Rate 5 Times in London Group - written by Mark Mascolini - (07/19/11) Two More Randomized Trials Show that Daily TDF/FTC Protects From HIV - written by Mark Mascolini - (07/19/11) Good Kidney and Liver Transplant Results in Large Study of People With HIV - written by Mark Mascolini - (07/19/11) Slow Drop in HIV Neurocognitive Disorder in Italian HIV Cohort: 'cognitive impairment persists in HIV-positive people.....' - written by Mark Mascolini - (07/19/11) Rilpivirine (TMC278) vs Efavirenz at 96 Weeks in Antiretroviral Naive - written by Mark Mascolini - (07/19/11) Lersivirine, a New NNRTI, Versus Efavirenz as First-Line Therapy: 48 Weeks - written by Mark Mascolini - (07/19/11) Similar 48-Week Response Rates With New Integrase Inhibitor and Efavirenz in Naives - written by Mark Mascolini - (07/19/11) Risk of Osteoporotic Fractures Associated with Cumulative Exposure to Tenofovir and Other Antiretroviral Agents - written by Mark Mascolini - (07/18/11) Brain-Breaching Antiretroviral Score Not Tied to Neuropsych Function in Canada - written by Mark Mascolini - (07/18/11) Antiretroviral Therapy Lowers HIV Transmission Risk in HIV+/HIV- Couples: "96% reduction in HIV transmission risk to an HIV-negative partner..... definitive proof of the concept that antiretroviral therapy lowers the risk HIV transmission" - written by Mark Mascolini - (07/18/11) Risk of Osteoporotic Fractures Associated with Cumulative Exposure to Tenofovir and Other Antiretroviral Agents - (07/18/11)